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Abstract: The majority of children awaiting heart transplantation require inotropic support, mechanical ventilation, and/or 
extracorporeal membrane oxygenation (ECMO) support. Unfortunately, due to the limited pool of organs, many of these 
children do not survive to transplant. Mechanical circulatory support of the failing heart in pediatrics is a new and rapidly 
developing field world-wide. It is utilized in children with acute congestive heart failure associated with congenital heart 
disease, cardiomyopathy, and myocarditis, both as a bridge to transplantation and as a bridge to myocardial recovery. The 
current arsenal of mechanical assist devices available for children is limited to ECMO, intra-aortic balloon 
counterpulsation, centrifugal pump ventricular assist devices, the DeBakey ventricular assist device Child; the Thoratec 
ventricular assist device; and the Berlin Heart. In the spring of 2004, five contracts were awarded by the National Heart, 
Lung and Blood Institute to support preclinical development for a range of pediatric ventricular assist devices and similar 
circulatory support systems. The support of early development efforts provided by this program is expected to yield 
several devices that will be ready for clinical trials within the next few years. Our work reviews the current international 
experience with mechanical circulatory support in children and summarizes our own experience since 2005 with the 
Berlin Heart, comparing the indications for use, length of support, and outcome between these modalities. 
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INTRODUCTION 
  Most pediatric patients listed for heart transplantation 
eventually require a high level of cardiac support before 
transplantation. Currently, over 85% patients undergoing 
heart transplantation within the Pediatric Heart Transplant 
Study (PHTS) were United Network of Organ Sharing status 
1 (heart failure requiring intravenous inotropes) [1]. Unfor-
tunately, due to the limited availability of donors, only 500 
children worldwide undergo cardiac transplantation yearly, 
and mortality while awaiting a suitable organ exceeds 20% 
[2]. This situation has led to increased interest in mechanical 
circulatory support (MCS) as a bridge to transplantation or 
recovery in the pediatric age group.  
  Pediatric MCS in the United States has been limited until 
recently to ECMO, the Bio-pump (Medtronic Bio-Medicus, 
Minneapolis, Minnesota), and adult systems adapted for 
pediatric support. New devices in the United States available 
for children are the implantable MicroMed DeBakey VAD 
Child (MicroMed Cardiovascular, Inc., Houston, Texas) and 
the Berlin Heart VAD (Berlin Heart AG, Berlin, Germany) 
which were granted Humanitarian Device Exemption (HDE), 
and compassionate use exemption, by the Food and Drug 
Administration (FDA), respectively. The purpose of this 
review is to discuss the use of MCS in the critically ill child  
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awaiting heart transplantation, and describe our own 
experience with the Berlin Heart VAD. 
CURRENT STATE OF THE ART 
  Implantation of MCS devices in children as a bridge to 
heart transplantation is not uncommon [3-7]. Both ECMO 
and VADs have been used successfully in children with 
cardiorespiratory failure. ECMO initially emerged as a 
support tool for children in respiratory failure, and subse-
quently has become the dominant modality of MCS in 
children. It is generally used for emergencies and short term 
support while VADs are better utilized for longer term 
support, mainly as a bridge to transplantation. In instances 
when recovery seems unlikely and transplantation is the 
eventful therapy, there is no advantage to employing the 
ECMO first if VAD technology is available. Based on our 
experience and the experience of Hetzer et al. [8], early 
application of VAD is crucial to avoid end-organ dysfunc-
tion related to inadequate systemic perfusion. A recent report 
by Blume et al. [9] documented favorable outcome in 
children supported by long term VADs. The report utilized 
the PHTS database to analyze outcomes in children listed for 
heart transplantation between 1993 and 2003 placed on VAD 
support. In the current era (2000-2003), 86% of the VAD 
supported patients underwent successful heart transplan-
tation. Survival to transplant was significantly poorer in 
patients with congenital heart disease and in smaller, youn-
ger patients. This report demonstrated that postransplantation 
survival for VAD supported children was not significantly 
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require MCS and was significantly superior to Status 1 
patients supported with ECMO. 
SHORT-TERM MCS 
1. ECMO 
  ECMO is still the most common type of MCS used in 
infants and children. Indications for ECMO include the pre 
and postoperative support in congenital heart disease, as well 
as cardiogenic shock associated with cardiomyopathies, 
acute myocarditis, and intractable arrhythmias [10]. In 
patients with congenital heart disease hypoxia and pulmo-
nary hypertension are the most common clinical conditions 
leading to ECMO support prior to surgery [10]. Failure to 
wean from cardiopulmonary bypass, cardiogenic shock 
associated with low cardiac output, and cardiac arrest in the 
immediate postoperative period, is the most common 
postoperative indications for ECMO [11]. While ECMO is 
an effective rescue device, it is generally limited to short- 
term use (less than a month), requires the patient’s immo-
bilization, precludes rehabilitation, and is associated with 
multiple potential complications including major bleeding 
and neurological sequelae. Based on the 2006 ECLS registry 
report, the mortality rate in pediatric patients supported by 
ECMO was approximately 60% [12]. This rate has been 
consistent over the last two decades. 
2. BioMedicus Centrifugal Pump (BCP) 
  The BCP (Medtronic BioMedicus, Eden Prairie, MN, 
USA) is a constant speed, nonpulsatile device which can be 
used in children of all ages. Compared with roller pumps, 
there is less hemolysis and less significant inflammatory 
response [13]. A flow probe is necessary with the centrifugal 
pump due to its afterload dependency, and the inadequate 
correlation between the set pump speed in RPM and the 
actual flow generated. Pump speed requires manual adjust-
ments when venous return decreases. It does not include an 
oxygenator and, therefore, MCS of children with biven-
tricular failure requires the use of two pump heads. This set-
up is possible although technically cumbersome in a neonate 
or infant and, therefore, in these patients, ECMO is 
preferred.  
  The use of a single BCP in the setting of postoperative 
cardiac arrest is suboptimal since severe biventricular failure 
in these children is expected. Intaoperative placement of this 
type of a centrifugal pump is more common for patients who 
cannot be weaned from CPB due to isolated left ventricular 
failure, such as in children with anomalous left coronary 
artery arising from the pulmonary artery, transposition of the 
great arteries following arterial switch, and donor heart 
dysfunction following transplantation [14]. When global 
biventricular failure is present, either biventricular BCP or 
ECMO support will be required. In special cases, unloading 
of the left ventricle by a left BCP will result in improvement 
in right ventricular filling, as well as improvement in tricus-
pid valve function [15] eliminating the need for biventricular 
support.  
  The operating room provides a controlled environment 
which allows assessment of BCP versus ECMO support. In 
this setting, a venous cannula is placed in the left atrium 
while clamping the right atrial or caval cannulae used for 
CPB. Right heart hemodynamic profile is monitored at 150 
ml/kg/min pump flow. If right atrial pressure, pulmonary 
artery pressure, and right ventricular function are satisfac-
tory, the patient is placed on full ventilatory support, while 
gas exchange in the oxygenator is temporarily interrupted. If 
gas exchange, metabolic balance, and hemodynamic profile 
are adequate, left BCP may be utilized. ECMO or biven-
tricular BCP are required if right sided failure is observed 
during this assessment [16]. Advantages of left BCP over 
ECMO in those children with pure LV failure is its relative 
ease of use, fast set-up time, low priming volume, and low-
level anticoagulation.  
  Both modalities are limited to similar short-term periods 
of support, which is largely responsible for the nearly 
identical hospital outcomes reported in 1999 by Duncan et 
al. [17] in a single center experience comparing BCP and 
ECMO use in children. In this report, approximately two 
thirds of patients supported with either modality were 
successfully weaned, and 40% in each group survived to 
hospital discharge. Long term follow-up of the same cohort 
of patients was reported [16]. The surviving children who 
required ECMO or BCP support demonstrated favorable 
long-term survival, overall general health, and cardiac 
outcomes. Poor neurological outcomes were more common 
in ECMO than in BCP-supported patients. More than 60% of 
the ECMO supported patients demonstrated moderate to 
severe neurological impairment, compared to 20% of the 
VAD survivors. This advantage may be related to the lower 
level of anti-coagulation required for VAD support, although 
the difference may also be related to the use of ECMO in 
instances of cardiac arrest and low cardiac output which 
might be expected to substantially increase the risk for 
neurological complications in neonates and infants. 
3. Intra-Aortic Balloon Counterpulsation (IABP) 
  One of the most common MCS devices in adults with left 
ventricular failure associated with ischemic heart disease is 
IABP.  IABP uses the concepts of systolic unloading and 
diastolic augmentation. Its use in children remains limited 
due to technical considerations related to small patient and 
blood vessel size which complicates insertion and renders 
the IABP less effective. Early concerns about whether effec-
tive counterpulsation was achievable in the highly elastic and 
distensible aorta of young children have proven unfounded 
[18].  
  Its clinical efficacy in adults with left ventricular failure 
was established in 1973 through a multicenter trial [19]. The 
first experience in children was reported by Pollock and his 
group from Toronto [20]. They successfully used the IABP 
in 6 of 14 children following cardiac surgery. A second 
single center study in 8 children (ages 6 weeks to 6 years 
old) supported by IABP postoperatively was performed by 
Veasy and his group in Salt Lake City between November 
1981 and November 1982 [21]. Four of the 8 were 
successfully placed on IABP, but 2 died after 5 and 10 days 
of support. The two youngest and smallest patients were the 
only long-term survivors. A more recent work describes the 
Royal Liverpool Children’s Hospital, postoperative IABP 48    Current Cardiology Reviews, 2010, Vol. 6, No. 1  Gazit et al. 
experience in children. 14 patients aged 7 days to 13 years 
were supported. Ten of the 14 patients (71%) were success-
fully weaned from the IABP, of whom 8 became long-term 
survivors (57%) [22]. A significant concern in children with 
postoperative cardiogenic shock is its association with 
biventricular failure rather than pure LV failure which is 
more common in adults with ischemic heart disease. Biven-
tricular support which cannot be achieved with IABP, leads 
to its limited use in pediatric patients.  
LONG TERM MCS 
1. Adult Systems Used for Pediatric Support-Heartmate 
VAD and ThoratecVAD (Thoratec Corp., Pleasanton, 
CA) 
  These adult FDA approved extracorporeal MCS devices 
have been used successfully in older children whose body 
surface area is greater than 1.4 m
2 [23-26]. A retrospective 
multicenter study conducted by Reinhartz and colleagues 
[25] in children and adolescents supported with the Thoratec 
VAD (November 1982 until December 1999) revealed 
overall favorable outcomes. 58 patients in 27 centers world-
wide were studied. Their mean age was 13.8 years (range, 7-
17 years), and mean weight and body surface area were 51.6 
kg (range, 17 to 93 kg) and 1.5 m
2  (range, 0.7-2.1 m
2), 
respectively. Overall survival in this cohort (71%) was 
similar to survival in adults supported by this device (58%-
71.6%) with a comparable average duration of support. 
Statistical analysis exposed congenital heart disease as a 
strong independent risk factor for death. Another concerning 
finding was that 27% of the subjects had neurologic compli-
cations, substantially higher than the 5-12% neurological 
complications in adults supported by the Thoratec VAD.  
2. The Micromed DeBakey VAD Child (Micromed 
Technology Inc., Houston TX, USA) 
  The DeBakey VAD Child  system consists of four 
subsystems: an implantable pump system, an external 
controller system, an external Clinical Data Acquisition 
System and an external Patient Home Support System. The 
blood pump, intended to provide mechanical assistance to 
the failing left ventricle, is a miniaturized, implantable, 
titanium, electromagnetically actuated axial flow pump. The 
pump is 1.2 inches (30.5 mm) in diameter, 3.0 inches (76.2 
mm) in length and weighs 95 grams. A titanium inflow 
cannula connects the pump to the ventricular apex and a 
Vascutek Gelweave vascular graft (outflow conduit) 
connects the pump to the aorta. Blood flow from the pump is 
measured by an ultrasonic flow probe placed around the 
outflow conduit. The flow probe's wiring is bundled with the 
pump motor's wiring in a polymer-coated assembly. The 
cable assembly exits the skin superior to the iliac crest on the 
right frontal portion of the body and attaches to the VAD's 
external controller system.  
  The DeBakey VAD Child was  authorized by the U.S. 
FDA (February 2004) for use in providing temporary left 
side mechanical circulatory support as a bridge to heart 
transplantation for pediatric patients (5-16 yeas old, with 
BSA > 0.7 m
2 and < 1.5 m
2) who are in NYHA Class IV end 
stage heart failure, are refractory to medical therapy, and 
who are listed for heart transplantation. Its use in children 
has been limited to date. A recent report by Fraser et al. [27] 
summarized a single center experience of 6 patients with the 
DeBakey VAD Child. The average age of the patients was 
11 years (range, 6 to 15 years) with a BSA of 0.8 to 1.7 m
2. 
The average duration of support was 39 days, with 84 days 
being the longest duration of support. Three of these patients 
were successfully transplanted, whereas three died during 
support before transplantation. 
3. Pneumatic Pulsatile Pediatric VADs-The Berlin Heart 
EXCOR and Medos HIA 
  These extracorporeal systems have provided successful 
MCS in children of all ages (Fig. 1). They provide a long 
term bridge to heart transplantation while allowing 
extubation, ambulation, and active physical therapy, unlike 
ECMO or centrifugal pump VADs. While the Berlin Heart 
EXCOR system has been used successfully in Europe since 
1991, the U.S. FDA has only recently approved the use of 
the Berlin Heart EXCOR Pediatric VAD under a limited 
investigational device exemption in the USA.  
  The Berlin Heart VAD (Berlin Heart AG, Berlin, 
Germany) consists of a paracorporeal, pneumatically driven 
pump (Fig. 2). The pump is made of a translucent, semirigid 
housing of polyurethane divided into a blood chamber and 
an air chamber by a three layer flexible diaphragm. 
Available pump stroke volumes are 10, 25, 30, 50, 60, and 
80 mL. The blood flow is directed by trifleaflet polyurethane 
valves mounted in the pediatric pumps (10, 25, 30 mL), 
whereas either tilting disc valves (Sorin Biomedical, Torino, 
Italy) or trileaflet polyurethane valves are available for the 
adult pump sizes (50, 60, 80 mL). All blood-contacting 
surfaces inside the pump, including the polyurethane valves, 
are coated with heparin by the Carmeda process (Carmeda, 
Upplands Väsby, Sweden). Cannulae are designed in various 
configurations to allow biventricular support for all age 
groups. They are made of silicone rubber with a smooth 
internal surface. The outside of the cannulae is covered with 
a Dacron (C. R. Bard, Haverhill, Pennsylvania) velour 
surface at the contact site with the abdominal wall to 
encourage scar tissue ingrowth, thereby minimize ascending 
infections (Fig. 3). The cannulae are designed to produce a 
considerably reduced afterload to the native heart in 
comparison with conventional CPB cannulae. All Berlin 
Heart EXCOR cannulae are made to exit the body through 
the upper abdominal wall. Inflow cannulation for the left 
ventricular assist device is typically completed via the left 
ventricular apex and outflow cannulation is to the ascending 
aorta. Right atrial to main pulmonary artery cannulation is 
the preferred method for right-sided support. The driving 
subunits apply negative pressure to facilitate inflow and 
positive pressure to drive outflow. There are three com-
pressor subunits. Two are driving the right and left pumps 
and the third is a backup unit which will take over in case of 
a  subunit failure. The backup unit is designed to allow 
adequate biventricular positive/negative pressures at a 
constant rate of 90 per minute should both subunits malfunc-
tion simultaneously. Manual operation of the pump is 
possible in case of complete electrical failure. The maximum 
positive driving pressure is 350 mm Hg, and the maximum 






















Fig. (1). This picture illustrates the RVAD and LVAD cannulae. The order of the cannulae, from right to left, is right atrial outflow, 


















Fig. (2). The Berlin Heart VAD (Berlin Heart AG, Berlin, Germany) consists of a paracorporeal, pneumatically driven pump. The pump is 
made of a translucent, semirigid housing of polyurethane divided into a blood chamber and an air chamber by a three layer flexible 
diaphragm. 
















Fig. (3). The Berlin Heart VAD cannulae are designed in various configurations to allow biventricular support for all age groups. They are 
made of silicone rubber with a smooth internal surface. As demonstrated in the exit sites in this figure, the outside of the cannulae is covered 
with a Dacron (C. R. Bard, Haverhill, Pennsylvania) velour surface at the contact site with the abdominal wall to encourage scar tissue 
ingrowth, thereby minimize ascending infections. 
 
available biventricular operating modes are synchronous, 
where both ventricles are filled and emptied in concert, 
asynchronous, where one ventricle is filled while the other is 
emptied, and separate, where each ventricle is cycling 
independently [28].  
  A recent retrospective analysis performed by Hetzer and 
associates in Berlin [8] compared outcomes of children who 
were supported by the Berlin Heart EXCOR between 1991 
and 1998 (period 1; n=34), and children supported by this 
device between 1999 and 2004 (period 2; n=28). The 
primary outcomes were survival (defined as 30-day survival, 
heart transplantation, or myocardial recovery) and hospital 
discharge, namely, discharge home or to a rehabilitation 
center. Discharge from the hospital after either weaning from 
the system or heart transplantation was achieved for 35% in 
period 1 and for 68% in period 2 (p=0.029). Whereas in 
period 1 there were no survivors in the group of children 
younger than 1 year old, during period 2, survival in this age 
group was similar to that of the two groups of older children 
(p  =0.024). There was a significant improvement in the 
discharge rate in period 2 in patients with cardiomyopathy 
(43% versus 76%, p  = 0.045) and postcardiotomy heart 
failure (0% versus 57%, p= 0.01). The significant difference 
in outcomes is reflected in the experience accumulating 
worldwide in MCS for children.  
  The first child implanted with the Berlin Heart EXCOR 
in North America (University of Arizona College of 
Medicine, Tucson, Arizona) was a 9 year old child with 
tricuspid insufficiency [29]. Over 160 have now been 
supported by this device in North America through 
September 2008 [2]. The device has been used in over 30 US 
medical centers. Malaisrie et al. at Stanford, California have 
described their experience in 8 children, aged 4 to 55 months 
[30]. All patients were in cardiogenic shock requiring 
multiple inotropes. Five patients (63%) were successfully 
bridged to transplantation; of these, 4 were discharged home 
and 1 died from early graft failure. Five patients developed 
post-operative neurologic events. Device exchange was 
performed in 4 patients in the intensive care unit.  
  We have implanted Berlin Heart BiVADs in 13 patients 
from April 2005 to August 2008 [31] The median age of the 
patients was 2 years (12 days to 17 years). The median 
patient weight was 10.3 kg (3 to 45 kg). The etiology of 
heart failure was cardiomyopathy in 11 children and com-
plex congenital heart disease in 2. All children were 
supported with multiple intravenous inotropes ± mechanical 
ventilation (9 patients) or ECMO (4 patients) prior to 
BiVAD implantation. All had severe systemic ventricular 
dysfunction. At least moderate right ventricular dysfunction, 
as defined by a 2-dimensional echocardiographic ejection 
fraction less than 40%, was present in all patients. The 
median ventilatory requirement post VAD insertion was 4 
days (1-22 days). The median length of stay in the intensive 
care unit was 8.8 days (1-65 days). The median duration of 
VAD support was 33 days (1-77 days). Twelve of the 13 
patients (92%) who received VADs survived the period of 
circulatory support. A 3 kg baby who required immediate 
ECMO following birth died from anuric renal failure post 
Berlin Heart insertion. Three patients had 4 infectious 
complications. There was one episode of postoperative renal 
insufficiency not requiring dialysis. There were 18 total 
pump changes secondary to fibrin deposition or thrombus in 
8 patients. One patient suffered a hemidiaphragm paralysis 
necessitating plication. There was an acute mechanical 
failure of the IKUS driver in one instance, necessitating 
manual pumping until the substitute driver was attached. 
One patient required mediastinal reexploration in the very 
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been no acute neurologic complications and no 
thromboembolic events. Overall, 12 patients have thus far 
been successfully bridged to heart transplant. Post-transplant 
survival has been 100%, with a median follow-up of 24 
months. Postoperative anticoagulation is initiated with conti-
nuous infusion of heparin 24 hours after admission to the 
intensive care unit. Partial thromboplastin time is maintained 
between 40 and 51 seconds during the first 72 hours and 52 
to 80 seconds thereafter. Chronic anticoagulation has 
included: 1. subcutaneous low molecular weight heparin 
initiated at 1 mg/kg/dose twice daily and the dose is titrated 
to maintain the anti factor XA level between 0.75 and 1.0 
units per milliliter, 2. Aspirin, 5 mg/kg/dose twice daily, and 
3. Dipyridamole, 1 mg/kg/dose four times per day. 
ISSUES TO BE RESOLVED  
1. Single Versus Biventricular Support 
  Our experience, albeit limited, demonstrates the feasi-
bility of routine use of biventricular (BiVAD) support in 
pediatric patients. Children, unlike adults, tend to have 
significant biventricular involvement as well as increased 
pulmonary vascular resistance associated with severe 
decompensated heart failure. The pediatric sized hardware 
facilitated the implantation, and other than slightly longer 
operative times, we have not encountered significant 
disadvantages to the addition of the right VAD. We propose 
that BiVAD support simplifies postoperative management by 
elimination of the adverse pathophysiological consequences 
of right ventricular dysfunction. Another significant benefit 
is improved liver synthetic function contributing to better 
control of postoperative coagulopathy as well as intravas-
cular oncotic pressure. Adequate oncotic pressure may 
promote optimization of extravascular lung water as well as 
better renal perfusion and diuresis. These beneficial 
physiological consequences may facilitate earlier extubation 
and therefore more expeditious recovery. 
  Criteria to guide decision making in regards to the need 
for biventricular support are not clear-cut. Studies performed 
by Farrar et al. [33], and Kormos et al. [34] in adults 
concluded that the need for biventricular support is more 
dependent on the adult patient’s clinical status than on 
hemodynamic parameters. Unfortunately, there are no clear 
criteria to guide decision making in regards to the need for 
biventricular support in children with AHFS. These indi-
cators include impaired mental status, fever in the absence of 
infection, creatinine level and mixed venous oxygen 
saturation. Another notable variable was the increased need 
for blood transfusions in patients eventually requiring 
biventricular support. This was caused by diffuse bleeding 
unrelated to obvious surgical problems while supported with 
LVAD alone.  
2. MCS as a Bridge to Ventricular Recovery 
  Current studies support the use of MCS as a bridge to 
transplantation [8]. Both in adults and children the frequency 
of myocardial recovery in patients supported by long term 
mechanical assist devices is low. According to the Berlin 
Heart Institute’s results for the Berlin Heart Excor, between 
January 1990 and June 2006, 11 children out of 74 were 
weaned off the device. In the era between October 2000 and 
June 2006, 8 out of 34 children were weaned and 18 
underwent heart transplantation [35]. No child died after 
weaning. Of those who were weaned in the new era, one had 
myocarditis, 2 had cardiomyopathy, and 5 congenital heart 
disease. Out of the 154 adult patients supported by long term 
VADs at the University of Pittsburgh [36], 6.5% recovered 
ventricular function sufficient for device removal. Eighty 
percent of the patients bridged to recovery carried the 
diagnoses of acute myocarditis or post-partum cardiomyo-
pathy. These results were consistent with those of a previous 
multicenter study published by Farrar et al. in 2002 [37]. 
With increased availability of the Berlin Heart in North 
America and Europe, further insight into the clinical scena-
rios where VADs can be used for myocardial recovery in 
pediatric heart failure should be forthcoming in the near 
future.  
3. Neurological Complications 
  According to the experience of Hetzer et al. [8] which 
was summarized above, 2 of 28 children supported by the 
modified system between 1999 and 2004 suffered cerebral 
strokes. Our patients [31] had no neurological complications, 
however, since our anticoagulation regime described above 
is not significantly different from that described by Hetzer et 
al [8], and the number of patients supported by the Berlin-
heart VAD in our center is smaller, index of suspicion for 
cerebral strokes in our future patients shall remain high.  
4. Sensitization to Human Leukocyte Antigens (HLAs)  
  Patients with implantable VAD are at risk for developing 
antibodies to HLA during support. HLA sensitization is 
defined as didithiotreitol-treated T-cell panel-reactive 
antibody (PRA) titer greater than 10% immediately before 
transplantation. Data presented by McKenna et al. [38] 
suggest that HLA alloimunization may be due to extensive 
blood transfusion. This might be related to HLA found on 
leukocytes within the transfusions. According to Kumpati et 
al. [39], alloimunization during VAD support in adults is not 
constant but increases rapidly at implantation and then 
decreases. In this study, device type was not a predictor of 
sensitization. The presence of HLA antibodies can delay 
transplantation, as a negative prospective crossmatch is 
required, and require, per our protocol, pretransplantation 
administration of intravenous immunoglobulin G and cyclo-
phosphamide, as well as peritransplantation plasmapheresis 
and cyclophosphamide. In our Berlin-heart VAD supported 
patients, HLA sensitization occurred in 3 patients. All were 
supported longer than 30 days and all developed extremely 
elevated (>90%) PRA by enzyme-linked immunosorbent 
assay. None had positive donor-specific T or B cell retro-
spective crossmatch. In our patients there has been one 
episode of rejection with hemodynamic compromise [31].  
5. Combination of BiVAD Support and Medical 
Pulmonary Vasodilator Therapy in Children with 
“Fixed” Pulmonary Hypertension  
  Based on our experience [40],even children with extreme 
pulmonary hypertension related to congenital heart disease 
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instead of heart-lung transplant, if treated with BiVAD 
combined with medical pulmonary vasodilator therapy. In 2 
patients with pulmonary vascular resistance index (Rpi)> 
10WU x m
2 unresponsive to pulmonary vasodilator therapy 
alone, Rpi decreased to 1.4 and 4.6 WU x m
2, after 33 and 41 
days of support, respectively. Pulmonary vascular resistance 
remained normal without pulmonary vasodilators in these 
patients within 3 months after heart transplant.
  
THE FUTURE 
  The need for pediatric miniaturized long-term MCS 
devices fit for use in all age groups including neonates led 
the U.S. National Heart, Lung, and Blood Institute (NHLBI) 
to provide funding for their development [32]. The NHLBI is 
currently supporting five MCS development programs across 
the country. These 5-years programs were awarded on March 
30, 2004 and include the PediaFlow VAD (University of 
Pittsburgh), The PediPump (The Cleveland Clinic Foun-
dation), Pediatric Cardiopulmonary Assist System (Ension, 
Inc), The Pediatric Jarvik 2000 (Jarvik Heart), and the 
Pediatric Ventricular Assist Device (Penn State). The goal of 
the program is to have these devices ready to begin human 
trials at the completion of the funding period in 2009. Each 
one of these devices has unique features, and the expectation 
is that the 5 devices shall provide solutions to different 
pediatric clinical conditions. 
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